Myriad Genetics IncMYGN
Price$4.06

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $806.6M-3.7% YoYTTM through 30 Jun 2026
Net Income -$112.6MTTM through 30 Jun 2026
Free Cash Flow -$49.4MTTM through 30 Jun 2026

Margins

Current
Gross Margin68.7%
EBITDA Margin-6.0%
Operating Margin-15.3%
Net Margin-14.0%

Returns

-10.1%ROE
-59.4%ROA

Balance Sheet Health

Debt / Equity0.36x
Current Ratio2.12x
Net Debt-$4.1Mnet cash position
Cash & Equivalents$115.2M

Quality Metrics

Altman Z-Score-0.89
Piotroski F-Score4 / 9
FCF Margin-6.1%
Rule of 400.9
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'20'20'21'22'23'24'25
FY2025: $824.5M
Diluted EPS-$1.18TTM
'20'20'21'22'23'24'25
FY2025: $-3.95

Dividend

No dividend

Capital Allocation

R&D Spend$105.8M
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.